Anzeige
Erschienen in:
01.12.2011 | Congress Report: Summaries
Summaries from the 65th Annual Meeting of the Japan Esophageal Society on September 26, 2011, Sendai
Erschienen in: Esophagus | Ausgabe 4/2011
Einloggen, um Zugang zu erhaltenExcerpt
We chaired the symposium, “Guidelines for diagnosis and treatment of carcinoma of the esophagus”, at the 65th Annual Meeting of the Japan Esophageal Society. We report here the revisions and summarize the discussions. As described in the first and second edition, the Esophageal Cancer Therapy Guidelines have been prepared for routine medical treatment of esophageal cancer by many facilities, and to recommend standard therapies currently considered to be the most adequate. However, there are various problems with regard to therapeutic policy on esophageal cancer, and there are many difficulties in the standardization of therapeutic methods. The revisions are as follows:
1.
“Epidemiology” has been newly added. In the section of “Epidemiology”, “Prevalence”, “Mortality rate” and “Risk factor” have been described.
2.
“Perioperative care” and “Clinical pathway” have been added, and they have been described in the section of “Surgical treatments”.
3.
In the section of “Surgical treatments”, “Salvage surgery” has been added.
4.
“Barrett’s esophagus” and “Barrett’s esophageal carcinoma” have been added.
5.
Treatment of “Multiple primary cancer” has been described.
6.
We are considering whether a new chapter should be added regarding “European and American guidelines”.
7.
“Clinical Question” was continued. Classification of the recommendation level was changed as follows.
A.
Implementation is strongly recommended.
B.
Implementation is recommended.
C1.
There is no clear evidence but implementation is recommended.
C2.
There is no clear evidence but avoiding implementation is recommended.
D.
Avoiding implementation is recommended.
8.
One of the aims of this revision was positioning of neoadjuvant chemotherapy.
9.
“Algorithm for treatment of esophageal carcinoma” was changed.